HRP20221208T1 - Depot sustav koji sadrži glatiramer acetat - Google Patents
Depot sustav koji sadrži glatiramer acetat Download PDFInfo
- Publication number
- HRP20221208T1 HRP20221208T1 HRP20221208TT HRP20221208T HRP20221208T1 HR P20221208 T1 HRP20221208 T1 HR P20221208T1 HR P20221208T T HRP20221208T T HR P20221208TT HR P20221208 T HRP20221208 T HR P20221208T HR P20221208 T1 HRP20221208 T1 HR P20221208T1
- Authority
- HR
- Croatia
- Prior art keywords
- glatiramer acetate
- pharmaceutical preparation
- water
- pharmaceutically acceptable
- microparticles
- Prior art date
Links
- 108010072051 Glatiramer Acetate Proteins 0.000 title claims 9
- FHEAIOHRHQGZPC-KIWGSFCNSA-N acetic acid;(2s)-2-amino-3-(4-hydroxyphenyl)propanoic acid;(2s)-2-aminopentanedioic acid;(2s)-2-aminopropanoic acid;(2s)-2,6-diaminohexanoic acid Chemical compound CC(O)=O.C[C@H](N)C(O)=O.NCCCC[C@H](N)C(O)=O.OC(=O)[C@@H](N)CCC(O)=O.OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 FHEAIOHRHQGZPC-KIWGSFCNSA-N 0.000 title claims 8
- 229960003776 glatiramer acetate Drugs 0.000 title claims 8
- 238000000034 method Methods 0.000 claims 9
- 239000000825 pharmaceutical preparation Substances 0.000 claims 6
- 239000011859 microparticle Substances 0.000 claims 5
- 229920001244 Poly(D,L-lactide) Polymers 0.000 claims 4
- 229920001606 poly(lactic acid-co-glycolic acid) Polymers 0.000 claims 4
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims 3
- 201000006417 multiple sclerosis Diseases 0.000 claims 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 3
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims 2
- 239000004372 Polyvinyl alcohol Substances 0.000 claims 2
- 229960003767 alanine Drugs 0.000 claims 2
- 238000004108 freeze drying Methods 0.000 claims 2
- 239000003960 organic solvent Substances 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 229920002451 polyvinyl alcohol Polymers 0.000 claims 2
- 230000002035 prolonged effect Effects 0.000 claims 2
- 239000002904 solvent Substances 0.000 claims 2
- 239000004094 surface-active agent Substances 0.000 claims 2
- 229960004441 tyrosine Drugs 0.000 claims 2
- 239000007762 w/o emulsion Substances 0.000 claims 2
- YLOCGHYTXIINAI-XKUOMLDTSA-N (2s)-2-amino-3-(4-hydroxyphenyl)propanoic acid;(2s)-2-aminopentanedioic acid;(2s)-2-aminopropanoic acid;(2s)-2,6-diaminohexanoic acid Chemical compound C[C@H](N)C(O)=O.NCCCC[C@H](N)C(O)=O.OC(=O)[C@@H](N)CCC(O)=O.OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 YLOCGHYTXIINAI-XKUOMLDTSA-N 0.000 claims 1
- RTBFRGCFXZNCOE-UHFFFAOYSA-N 1-methylsulfonylpiperidin-4-one Chemical compound CS(=O)(=O)N1CCC(=O)CC1 RTBFRGCFXZNCOE-UHFFFAOYSA-N 0.000 claims 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims 1
- QNAYBMKLOCPYGJ-UHFFFAOYSA-N D-alpha-Ala Natural products CC([NH3+])C([O-])=O QNAYBMKLOCPYGJ-UHFFFAOYSA-N 0.000 claims 1
- QNAYBMKLOCPYGJ-UWTATZPHSA-N L-Alanine Natural products C[C@@H](N)C(O)=O QNAYBMKLOCPYGJ-UWTATZPHSA-N 0.000 claims 1
- -1 L-glutaric acid Chemical compound 0.000 claims 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims 1
- 239000004472 Lysine Substances 0.000 claims 1
- 229930195725 Mannitol Natural products 0.000 claims 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 235000004279 alanine Nutrition 0.000 claims 1
- JFCQEDHGNNZCLN-UHFFFAOYSA-N anhydrous glutaric acid Natural products OC(=O)CCCC(O)=O JFCQEDHGNNZCLN-UHFFFAOYSA-N 0.000 claims 1
- 239000008346 aqueous phase Substances 0.000 claims 1
- 229920001400 block copolymer Polymers 0.000 claims 1
- 229920002678 cellulose Polymers 0.000 claims 1
- 238000005119 centrifugation Methods 0.000 claims 1
- 239000002577 cryoprotective agent Substances 0.000 claims 1
- 239000002552 dosage form Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 239000000839 emulsion Substances 0.000 claims 1
- 238000001704 evaporation Methods 0.000 claims 1
- 230000008020 evaporation Effects 0.000 claims 1
- 238000001914 filtration Methods 0.000 claims 1
- 229940042385 glatiramer Drugs 0.000 claims 1
- 239000012729 immediate-release (IR) formulation Substances 0.000 claims 1
- 238000002513 implantation Methods 0.000 claims 1
- 235000018977 lysine Nutrition 0.000 claims 1
- 239000000594 mannitol Substances 0.000 claims 1
- 235000010355 mannitol Nutrition 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000011325 microbead Substances 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 229920001451 polypropylene glycol Polymers 0.000 claims 1
- 229920000136 polysorbate Polymers 0.000 claims 1
- 229950008882 polysorbate Drugs 0.000 claims 1
- 238000002360 preparation method Methods 0.000 claims 1
- 239000008213 purified water Substances 0.000 claims 1
- 239000007787 solid Substances 0.000 claims 1
- WPLOVIFNBMNBPD-ATHMIXSHSA-N subtilin Chemical compound CC1SCC(NC2=O)C(=O)NC(CC(N)=O)C(=O)NC(C(=O)NC(CCCCN)C(=O)NC(C(C)CC)C(=O)NC(=C)C(=O)NC(CCCCN)C(O)=O)CSC(C)C2NC(=O)C(CC(C)C)NC(=O)C1NC(=O)C(CCC(N)=O)NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C1NC(=O)C(=C/C)/NC(=O)C(CCC(N)=O)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)CNC(=O)C(NC(=O)C(NC(=O)C2NC(=O)CNC(=O)C3CCCN3C(=O)C(NC(=O)C3NC(=O)C(CC(C)C)NC(=O)C(=C)NC(=O)C(CCC(O)=O)NC(=O)C(NC(=O)C(CCCCN)NC(=O)C(N)CC=4C5=CC=CC=C5NC=4)CSC3)C(C)SC2)C(C)C)C(C)SC1)CC1=CC=CC=C1 WPLOVIFNBMNBPD-ATHMIXSHSA-N 0.000 claims 1
- 230000009885 systemic effect Effects 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 claims 1
- 238000005406 washing Methods 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/10—Peptides having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
- A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1682—Processes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poly(lactide-co-glycolide)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5089—Processes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/02—Peptides of undefined number of amino acids; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
Claims (14)
1. Postupak proizvodnje parenteralne farmaceutskog pripravka s produljenim djelovanjem koji sadrži glatiramer acetat i farmaceutski prihvatljiv biorazgradivi nosač odabran između skupine koja sadrži poli(D,L-laktid) (PLA) i poli(D,L-laktid-ko-glikolid) (PLGA); taj postupak sadrži korake:
(i) raspršivanja koncentriranog otapala glatiramer acetata u nekom otapalu farmaceutski prihvatljivog biorazgradivog nosača u isparljivom organskom otapalu koji se može uroniti u vodu, čime se dobija emulzija vode u ulju,
(ii) raspršivanje navedene emulzije vode u ulju u kontinuiranoj vanjskoj vodenastoj fazi koja sadrži surfaktant da bi se stvorile kapljice dvostruke emulzije vode u ulju u vodi,
(iii) isparavanje navedenog organskog otapala, čime se dobivaju mikročestice u krutom obliku,
(iv) prikupljanje navedenih mikročestica filtriranjem ili centrifugiranjem.
2. Postupak sukladno patentnom zahtjevu 1, nadalje sadrži korak
(v) pranja navedenih prikupljenih mikročestica s pročišćenom vodom.
3. Postupak sukladno patentnom zahtjevu 1 ili 2, nadalje sadrži korak (vi) liofilizacije navedenih prikupljenih mikročestica.
4. Postupak sukladno patentnom zahtjevu 3, nadalje sadrži korak
(vii) rekonstituiranja navedenih liofiliziranih mikročestica.
5. Postupak sukladno patentnom zahtjevu 1 do 4, pri čemu je taj farmaceutski prihvatljiv biorazgradivi nosač PLGA.
6. Postupak sukladno patentnom zahtjevu 1 do 5, pri čemu je surfaktant odabran između skupine koja sadrži polivinil alkohol (PVA), polisorbat, kopolimere bloka polietilen oksida polipropilen oksida i celuloznog estera.
7. Postupak sukladno patentnom zahtjevu 1 do 6, pri čemu je liofilizacija navedenih mikročetica uz prisutnost krioprotektanta, poželjno manitola.
8. Parenteralni farmaceutski pripravak s dugim djelovanjem koje sadrži glatiramer acetat i farmaceutski prihvatljiv biorazgradivi nosač je odabran između skupine koja sadrži poli(D,L-laktid) (PLA) i poli(D,L-laktid-ko-glikolid) (PLGA) koji se može dobiti postupkom sukladno bilo kojem od patentnih zahtjeva 1 do 7.
9. Farmaceutski pripravak sukladno patentnom zahtjevu 8, pri čemu je farmaceutski prihvatljiv biorazgradiv nosač PLGA.
10. Farmaceutski pripravak sukladno patentnom zahtjevu 8 ili 9, pri čemu glatiramer acetat sadrži L-alanin, L-glutarnu kiselinu, L-lizin, i L-tirozin u molarnim odnosima od 0,14 glutarne kiseline, 0,43 alanina, 0,10 tirozina i 0,33 lizina.
11. Farmaceutski pripravak sukladno patentnim zahtjevima 8 do 10, koja je pohranjen u obliku podobnom za implantaciju na medicinski prihvatljivom mjestu kod subjekta kojem je potrebna i/ili koja je pogodna za raspored doziranja odjednom svaka 2 tjedna do jednom mjesečno.
12. Farmaceutski pripravak sukladno patentnom zahtjevu 8 do 11 radi liječenja multiple skleroze.
13. Farmaceutski pripravak za uporabu u liječenju multiple skleroze sukaldno patentnom zahtjevu 12, pri čemu taj pripravak osigurava jednaku ili superironu terapijsku učinkovitost za komercijalno dostupne dnevne injektibilne oblike doze glatiramer acetata, sa smanjenom učestalošću i/ili ozbiljnošću neželjenih učinaka na lokalnoj i/ili sistemskoj razini;
i pri čemu taj pripravak nadalje osigurava produljeno otpuštanje ili produljen učinak glatiramera kod subjekta u usporedbi s pretežito sličnom dozom formulacije s neposrednim otpuštanjem glatiramer acetata.
14. Farmaceutski pripravak za uporabu u liječenje multiple skleroze sukladno patentnom zahtjevu 12 ili 13, pri čemu se taj glatiramer acetat daje u kombinaciji s najmanje jednim drugim aktivnim sastojkom.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US29192810P | 2010-01-04 | 2010-01-04 | |
| EP18205308.2A EP3536333B1 (en) | 2010-01-04 | 2010-08-19 | Depot system comprising glatiramer acetate |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20221208T1 true HRP20221208T1 (hr) | 2022-12-09 |
Family
ID=44226217
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20221208TT HRP20221208T1 (hr) | 2010-01-04 | 2010-08-19 | Depot sustav koji sadrži glatiramer acetat |
| HRP20182076TT HRP20182076T1 (hr) | 2010-01-04 | 2018-12-10 | Sustav s kontroliranim otpuštanjem koji obuhvaća glatiramer acetat |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20182076TT HRP20182076T1 (hr) | 2010-01-04 | 2018-12-10 | Sustav s kontroliranim otpuštanjem koji obuhvaća glatiramer acetat |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US8796226B2 (hr) |
| EP (2) | EP2398488B1 (hr) |
| JP (2) | JP5916622B2 (hr) |
| CN (3) | CN107661490B (hr) |
| AU (1) | AU2010337822B2 (hr) |
| BR (1) | BR112012016459B1 (hr) |
| CA (1) | CA2784394C (hr) |
| CY (1) | CY1120975T1 (hr) |
| DK (2) | DK3536333T3 (hr) |
| ES (2) | ES2699692T3 (hr) |
| HK (2) | HK1245667A1 (hr) |
| HR (2) | HRP20221208T1 (hr) |
| HU (2) | HUE040390T2 (hr) |
| LT (2) | LT2398488T (hr) |
| MX (2) | MX2020003805A (hr) |
| PL (2) | PL2398488T3 (hr) |
| PT (2) | PT2398488T (hr) |
| SI (1) | SI2398488T1 (hr) |
| TR (1) | TR201818858T4 (hr) |
| WO (1) | WO2011080733A1 (hr) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8377885B2 (en) | 2010-01-04 | 2013-02-19 | Mapi Pharma Ltd. | Depot systems comprising glatiramer or pharmacologically acceptable salt thereof |
| USRE49251E1 (en) | 2010-01-04 | 2022-10-18 | Mapi Pharma Ltd. | Depot systems comprising glatiramer or pharmacologically acceptable salt thereof |
| EP2699317B1 (en) | 2011-04-21 | 2016-08-10 | Mapi Pharma Limited | Random pentapolymer for treatment of autoimmune diseases |
| WO2013038399A1 (en) | 2011-09-18 | 2013-03-21 | Bio Plasmar Ltd | Bio-degradable compositions and use thereof |
| WO2014128079A1 (en) * | 2013-02-19 | 2014-08-28 | Synthon B.V. | Glatiramer acetate multidose formulation |
| CN103169670B (zh) * | 2013-03-22 | 2016-07-06 | 深圳翰宇药业股份有限公司 | 一种醋酸格拉替雷微球及其制备方法 |
| US20160128951A1 (en) * | 2013-07-29 | 2016-05-12 | Aizant Drug Research Solutions Pvt Ltd | Pharmaceutical compositions of fingolimod |
| WO2015100370A2 (en) * | 2013-12-23 | 2015-07-02 | Kineta One, Llc | Sustained release depot formulations of therapeutic proteins, and uses thereof |
| US10493122B2 (en) | 2014-03-17 | 2019-12-03 | Mapi Pharma Ltd. | Sublingual delivery of glatiramer acetate |
| EP3352735B1 (en) | 2015-09-21 | 2023-08-30 | Teva Pharmaceuticals International GmbH | Sustained release olanzapine formulations |
| WO2018002930A1 (en) * | 2016-06-30 | 2018-01-04 | Stem Cell Medicine Ltd. | Treatment of inflammatory bowel disease with long acting glatiramer and adipose-derived stem cells |
| MX2019001999A (es) * | 2016-08-28 | 2019-08-29 | Mapi Pharma Ltd | Proceso para la preparacion de microparticulas que contienen acetato de glatiramer. |
| HRP20230738T1 (hr) | 2016-08-31 | 2023-10-27 | Mapi Pharma Ltd | Depo sustavi koji sadrže glatiramer acetat |
| AU2016428204B2 (en) * | 2016-10-28 | 2019-09-26 | SpineThera | Pharmaceutical compositions and uses thereof |
| EP3600258A1 (en) | 2017-03-20 | 2020-02-05 | Teva Pharmaceuticals International GmbH | Sustained release olanzapine formulaitons |
| WO2018178973A1 (en) * | 2017-03-26 | 2018-10-04 | Mapi Pharma Ltd. | Glatiramer depot systems for treating progressive forms of multiple sclerosis |
| JP2020519645A (ja) | 2017-05-15 | 2020-07-02 | ステム セル メディスン リミテッド | 脂肪組織由来幹細胞による多発性硬化症の治療 |
| JP7000458B2 (ja) * | 2017-05-15 | 2022-02-10 | ステム セル メディスン リミテッド | 長時間作用性グラチラマー及び脂肪由来幹細胞での多発性硬化症の治療 |
| US10323289B2 (en) | 2017-06-26 | 2019-06-18 | Institut Pasteur | Treatments to eliminate HIV reservoirs and reduce viral load |
| WO2022003662A1 (en) * | 2020-06-29 | 2022-01-06 | Mapi Pharma Ltd. | Low burst-release liraglutide depot systems |
| EP4236990A1 (en) * | 2020-11-02 | 2023-09-06 | Simcha Il-18, Inc. | Interleukin-18 variants and methods of use |
| EP4277661A1 (en) | 2021-01-18 | 2023-11-22 | Anton Frenkel | Pharmaceutical dosage form |
| JP2024507598A (ja) * | 2021-01-29 | 2024-02-21 | ティオンラボ・セラピューティクス | 初期放出制御されたデポー組成物及びその製造方法 |
| US11865213B2 (en) | 2021-07-05 | 2024-01-09 | Mapi Pharma Ltd. | Semaglutide depot systems and use thereof |
| WO2023281406A1 (en) | 2021-07-06 | 2023-01-12 | Mark Hasleton | Treatment of serotonin reuptake inhibitor withdrawal syndrome |
| WO2023170493A1 (en) * | 2022-03-07 | 2023-09-14 | Hadidi Naghmeh | Drug delivery using a parenteral pharmaceutical composition |
| WO2024054879A1 (en) * | 2022-09-06 | 2024-03-14 | Regents Of The University Of Michigan | Biodegradable polymeric particles for delivery of positively charged therapeutic agents |
Family Cites Families (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3536809A (en) | 1969-02-17 | 1970-10-27 | Alza Corp | Medication method |
| US3598123A (en) | 1969-04-01 | 1971-08-10 | Alza Corp | Bandage for administering drugs |
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| IL36670A (en) | 1971-04-21 | 1974-09-10 | Sela M | Therapeutic basic copolymers of amino acids |
| US3845770A (en) | 1972-06-05 | 1974-11-05 | Alza Corp | Osmatic dispensing device for releasing beneficial agent |
| US3916899A (en) | 1973-04-25 | 1975-11-04 | Alza Corp | Osmotic dispensing device with maximum and minimum sizes for the passageway |
| US4008719A (en) | 1976-02-02 | 1977-02-22 | Alza Corporation | Osmotic system having laminar arrangement for programming delivery of active agent |
| IE58110B1 (en) | 1984-10-30 | 1993-07-14 | Elan Corp Plc | Controlled release powder and process for its preparation |
| GB2209937B (en) * | 1987-09-21 | 1991-07-03 | Depiopharm S A | Water insoluble polypeptides |
| US5073543A (en) | 1988-07-21 | 1991-12-17 | G. D. Searle & Co. | Controlled release formulations of trophic factors in ganglioside-lipsome vehicle |
| IT1229203B (it) | 1989-03-22 | 1991-07-25 | Bioresearch Spa | Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative. |
| US5120548A (en) | 1989-11-07 | 1992-06-09 | Merck & Co., Inc. | Swelling modulated polymeric drug delivery device |
| US5580578A (en) | 1992-01-27 | 1996-12-03 | Euro-Celtique, S.A. | Controlled release formulations coated with aqueous dispersions of acrylic polymers |
| US5591767A (en) | 1993-01-25 | 1997-01-07 | Pharmetrix Corporation | Liquid reservoir transdermal patch for the administration of ketorolac |
| US5800808A (en) | 1994-05-24 | 1998-09-01 | Veda Research And Development Co., Ltd. | Copolymer-1 improvements in compositions of copolymers |
| IT1270594B (it) | 1994-07-07 | 1997-05-07 | Recordati Chem Pharm | Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida |
| US5858964A (en) | 1995-04-14 | 1999-01-12 | Yeda Research And Development Co. Ltd. | Pharmaceutical compositions comprising synthetic peptide copolymer for prevention of GVHD |
| IT1276690B1 (it) | 1995-06-09 | 1997-11-03 | Ira Srl | Sistema di inclusione a rilascio controllato di acido glicolico in beta-ciclodestrine e procedimento di preparazione di detto sistema |
| US6214791B1 (en) | 1997-01-10 | 2001-04-10 | Yeda Research And Development Co. Ltd. | Treatment of multiple sclerosis through ingestion or inhalation of copolymer-1 |
| TW577759B (en) * | 1997-04-18 | 2004-03-01 | Ipsen Pharma Biotech | Sustained release compositions in the form of microcapsules or implants and the process for their preparation |
| ES2527760T3 (es) | 1998-07-23 | 2015-01-29 | Yeda Research And Development Co., Ltd. | Tratamiento de enfermedad de Crohn con copolímero 1 y polipéptidos |
| WO2000005250A1 (en) | 1998-07-23 | 2000-02-03 | Yeda Research And Development Co., Ltd | Treatment of autoimmune conditions with copolymer 1 and related copolymers and peptides |
| EP1128839A4 (en) | 1998-11-12 | 2002-10-09 | Yeda Res & Dev | PHARMACEUTICAL COMPOSITIONS CONTAINING COPOLYMERS OF SYNTHETIC PEPTIDES AND METHODS FOR PREVENTING AND TREATING GVHD AND HVGD |
| ATE302020T1 (de) | 2000-01-20 | 2005-09-15 | Yeda Res & Dev | Verwendung von copolymer 1- und verwandten peptiden sowie von polypeptiden und damit behandelten t-zellen zur neuroprotektiven therapie |
| JP4328090B2 (ja) | 2000-06-07 | 2009-09-09 | イエダ リサーチ アンド デベロップメント カンパニー リミテッド | 神経細胞の保護療法におけるコポリマー１、関連ペプチドおよびポリペプチドならびにそれらによって処理されたｔ細胞の使用 |
| US6835711B2 (en) | 2001-06-28 | 2004-12-28 | Yeda Research And Development Co. Ltd. | Use of poly-Glu,Tyr for neuroprotective therapy |
| JP4426286B2 (ja) * | 2001-07-10 | 2010-03-03 | テバ ファーマシューティカル インダストリーズ リミティド | ０次、０次−二相性、上昇型又は下降型薬物放出のための薬物送達システム |
| DE02800437T1 (de) | 2001-10-03 | 2004-11-11 | The President And Fellows Of Harvard College, Cambridge | Copolymere zur unterdrückung von autoimmunkrankheiten und anwendungsverfahren |
| US8871241B2 (en) | 2002-05-07 | 2014-10-28 | Psivida Us, Inc. | Injectable sustained release delivery devices |
| CN1398584A (zh) * | 2002-07-15 | 2003-02-26 | 裴福兴 | 一种bFGF－PLGA缓释微球及其制备方法和用途 |
| US20050142205A1 (en) | 2003-07-18 | 2005-06-30 | Julia Rashba-Step | Methods for encapsulating small spherical particles prepared by controlled phase separation |
| SG135204A1 (en) | 2003-07-18 | 2007-09-28 | Baxter Int | Methods for fabrication, uses and compositions of small spherical particles prepared by controlled phase separation |
| US20060276390A1 (en) * | 2003-07-31 | 2006-12-07 | Yeda Research And Development Co. Ltd. | Combined treatments comprising synthetic peptide copolymers for preventing graft rejection |
| WO2005041933A1 (en) * | 2003-10-31 | 2005-05-12 | Teva Pharmaceutical Industries, Ltd. | Nanoparticles for drug delivery |
| JP5306599B2 (ja) * | 2004-01-12 | 2013-10-02 | ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア | 長期間送達製剤 |
| KR20060125916A (ko) | 2004-03-01 | 2006-12-06 | 펩팀문, 인코포레이티드 | 자가면역 질병을 치료하기 위한 방법 및 조성물 |
| US7655221B2 (en) * | 2004-05-07 | 2010-02-02 | Peptimmune, Inc. | Methods of treating disease with random copolymers |
| US7517856B2 (en) * | 2005-10-11 | 2009-04-14 | Ben-Gurion University Of The Negev Research And Development Authority | Bioconjugates comprising sulfated polysaccharides and their uses |
| WO2008075365A1 (en) | 2006-12-20 | 2008-06-26 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Compositions and methods for treatment of age related degeneration of the retina |
| ES2402175T3 (es) * | 2007-07-11 | 2013-04-29 | Medicinova, Inc. | Tratamiento de una enfermedad neurodegenerativa progresiva con ibudilast |
| JP2011529078A (ja) * | 2008-07-25 | 2011-12-01 | ザ・ジョンズ・ホプキンス・ユニバーシティー | 自己免疫疾患を治療および予防するための方法および組成物 |
| US8377885B2 (en) | 2010-01-04 | 2013-02-19 | Mapi Pharma Ltd. | Depot systems comprising glatiramer or pharmacologically acceptable salt thereof |
-
2010
- 2010-08-19 ES ES10840699T patent/ES2699692T3/es active Active
- 2010-08-19 EP EP10840699.2A patent/EP2398488B1/en active Active
- 2010-08-19 DK DK18205308.2T patent/DK3536333T3/da active
- 2010-08-19 MX MX2020003805A patent/MX2020003805A/es unknown
- 2010-08-19 LT LTEP10840699.2T patent/LT2398488T/lt unknown
- 2010-08-19 LT LTEP18205308.2T patent/LT3536333T/lt unknown
- 2010-08-19 AU AU2010337822A patent/AU2010337822B2/en active Active
- 2010-08-19 CA CA2784394A patent/CA2784394C/en active Active
- 2010-08-19 DK DK10840699.2T patent/DK2398488T3/en active
- 2010-08-19 HU HUE10840699A patent/HUE040390T2/hu unknown
- 2010-08-19 CN CN201711120362.4A patent/CN107661490B/zh active Active
- 2010-08-19 PT PT10840699T patent/PT2398488T/pt unknown
- 2010-08-19 SI SI201031811T patent/SI2398488T1/sl unknown
- 2010-08-19 PL PL10840699T patent/PL2398488T3/pl unknown
- 2010-08-19 CN CN201710417220.8A patent/CN107184954A/zh active Pending
- 2010-08-19 TR TR2018/18858T patent/TR201818858T4/tr unknown
- 2010-08-19 US US13/258,808 patent/US8796226B2/en active Active
- 2010-08-19 BR BR112012016459A patent/BR112012016459B1/pt active IP Right Grant
- 2010-08-19 CN CN2010800606327A patent/CN102686235A/zh active Pending
- 2010-08-19 WO PCT/IL2010/000679 patent/WO2011080733A1/en active Application Filing
- 2010-08-19 MX MX2012007760A patent/MX349162B/es active IP Right Grant
- 2010-08-19 HR HRP20221208TT patent/HRP20221208T1/hr unknown
- 2010-08-19 PL PL18205308.2T patent/PL3536333T3/pl unknown
- 2010-08-19 HU HUE18205308A patent/HUE060304T2/hu unknown
- 2010-08-19 EP EP18205308.2A patent/EP3536333B1/en active Active
- 2010-08-19 PT PT182053082T patent/PT3536333T/pt unknown
- 2010-08-19 ES ES18205308T patent/ES2928900T3/es active Active
- 2010-08-19 JP JP2012546553A patent/JP5916622B2/ja active Active
-
2013
- 2013-01-17 HK HK18105428.1A patent/HK1245667A1/zh unknown
-
2015
- 2015-11-20 JP JP2015227317A patent/JP2016074696A/ja not_active Withdrawn
-
2018
- 2018-03-06 HK HK18103162.6A patent/HK1244430A1/zh unknown
- 2018-12-07 CY CY181101307T patent/CY1120975T1/el unknown
- 2018-12-10 HR HRP20182076TT patent/HRP20182076T1/hr unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20221208T1 (hr) | Depot sustav koji sadrži glatiramer acetat | |
| JP2013516403A5 (hr) | ||
| EP3906918B1 (en) | Methods and compositions related to synthetic nanocarriers with rapamycin in a stable, super-saturated state | |
| FI2341905T4 (fi) | Pitkävaikutteisia formulaatioita, joissa käytetään ei-vesipitoisia kantajia | |
| CN101365423B (zh) | 缓释小分子药物制剂 | |
| HRP20170358T1 (hr) | Inhibitori histonskih demetilaza | |
| CN102119022A (zh) | 药物组合物 | |
| Luan et al. | In situ forming microparticle system for controlled delivery of leuprolide acetate: influence of the formulation and processing parameters | |
| CY1109425T1 (el) | Φαρμακευτικες συνθεσεις για τη χορηγηση με ελεγχομενη αποδεσμευση βιολογικα δραστικων ενωσεων | |
| CA2072812A1 (en) | Aerosol composition | |
| HRP20130109T4 (hr) | Formulacije kaspofungina | |
| KR101708517B1 (ko) | 일정하게 높은 노출 수준을 갖는 옥트레오티드 데포 제제 | |
| CA2900920C (en) | Microneedle coating composition and microneedle device | |
| JP6623084B2 (ja) | Ｓ／ｏ型貼付剤 | |
| JP2024010233A (ja) | リバスチグミンを含む長期持続型製剤およびその製造方法 | |
| KR101663561B1 (ko) | 서방출성 미립구의 제조방법 | |
| Koocheki et al. | Development of an enhanced formulation for delivering sustained release of buprenorphine hydrochloride | |
| JP2016527308A (ja) | エンテカビル微小球及びこれを含む非経口投与用医薬組成物 | |
| EA200971132A1 (ru) | Фармацевтическая композиция с пролонгированным высвобождением, приготовленная из микрочастиц | |
| CN1678352A (zh) | 贴剂 | |
| RU2017110076A (ru) | Фармацевтическая композиция и способы | |
| JP2019537551A5 (hr) | ||
| AU2017319781A1 (en) | Process for preparing microparticles containing glatiramer acetate | |
| US20110184057A1 (en) | Parenteral treatment with statins | |
| Algin-Yapar | Nasal inserts for drug delivery: an overview |